GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
GSK & Concert Pharmaceuticals to collaborate on deuterium-containing medicines, incl. CTP-518, a protease inhibitor for the treatment of HIV
Read the full article17y agoen
You might also wanna read
GSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
Chemistry World·23d ago
GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
Biotech firm is developing small molecules for lung cancers
cen.acs.org·29d ago
Rapid Drug Susceptibility Testing for Tuberculosis Using Raman-Deuterium Isotope Probing
Accurate and timely drug susceptibility testing (DST) is essential for tuberculosis (TB) management, especially given the global rise of mul
go.acs.org·4d agoStudy of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure
Conditions : HIV -1 Infection Interventions : Other: blood drawn Sponsors : Cliniques universitaires Saint-Luc- Université Catholique de Lou
clinicaltrials.gov·1d ago
Global protein-ligand binding affinity profiling via photocatalytic labeling
New approach integrates protein-ligand binding affinity profiling and photocatalytic labeling into a single step, enhancing drug discovery w
doi.org·16d ago
AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
Featured content
drugtargetreview.com·5mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.